BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/27/2022 10:06:45 AM | Browse: 202 | Download: 585
 |
Received |
|
2022-09-17 17:46 |
|
Peer-Review Started |
|
2022-09-17 17:48 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-10-30 18:26 |
|
Revised |
|
2022-11-04 21:55 |
|
Second Decision |
|
2022-11-28 03:21 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-11-29 00:04 |
|
Articles in Press |
|
2022-11-29 00:04 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-12-04 00:50 |
|
Typeset the Manuscript |
|
2022-12-20 14:25 |
|
Publish the Manuscript Online |
|
2022-12-27 10:06 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Chun-Ye Zhang, Shuai Liu and Ming Yang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ming Yang, DVM, PhD, Postdoctoral Fellow, Department of Surgery, University of Missouri, Room 2203, NexGen Precision Building, 1030 Hitt Street, Columbia, MI 65211, United States. yangmin@health.missouri.edu |
| Key Words |
Pancreatic cancer; Pancreatic ductal adenocarcinoma; Molecular mechanisms; Diagnostic and prognostic markers; Treatment; Clinical trials |
| Core Tip |
Pancreatic cancer (PC) is one of the malignancies that lead to causes of cancer death. Pancreatic ductal adenocarcinoma is the most common type of PC in the clinic. Multiple pathogenic processes including but not limited to inflammation, fibrosis, angiogenesis, epithelial-mesenchymal transition, and proliferation of cancer stem cells are involved in PC initiation and progression. Although some mono or combined therapies have been approved by the United States Food and Drug Administration for PC treatment, the overall 5-year survival rate is still very low. A combined panel of serum markers is very helpful for PC diagnosis. New treatments and more clinical trials are required to search for new potent therapeutic agents and evaluate their efficacy in PC treatment. |
| Publish Date |
2022-12-27 10:06 |
| Citation |
Zhang CY, Liu S, Yang M. Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options. World J Gastroenterol 2022; 28(48): 6827-6845 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i48/6827.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i48.6827 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
